Clinical Trial: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07229729) titled 'A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer' on Nov. 13.

Brief Summary: The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer

Intervention: DRUG: SHR-A2102

SHR-A2102.

DRUG: Adebrelimab

Adebrelimab.

DRUG: Paclitaxel

Paclitaxel.

DRUG: Carboplatin

Carboplatin.

DRUG: Alomnertinib Mesilate

Alomnertinib Mesilate.

D...